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Complete versus culprit-only revascularization in patients with multi-
vessel coronary disease undergoing primary percutaneous coronary
intervention: An updated meta-analysis of randomized trials
Islam Y. Elgendy,1 Xuerong Wen,1 Ahmed Mahmoud,1
Anthony A. Bavry1
1University of Florida, Gainesville, FL
BACKGROUND Current guidelines recommend against revasculari-
zation for non-culprit signiﬁcant coronary lesions at the time of pri-
mary percutaneous coronary intervention (PCI). The aim of this study
was to evaluate outcomes for patients with multi-vessel coronary
disease who underwent complete versus culprit-only revasculariza-
tion at the time of primary PCI.
METHODS Electronic databases and major conference proceedings were
searched for studies that randomized ST-elevation myocardial infarction
(MI) patients with multi-vessel disease to a complete versus culprit-only
revascularization strategy. The primary outcome was the combined
outcome of all-cause mortality or MI. Random effects summary risk ratios
(RR) were constructed using a DerSimonian–Laird model.
RESULTS A total of 7 studies with 1,939 patients were available for
analysis. The median procedure time and contrast volume was higher
in the complete revascularization group versus the culprit-only group
(67.3  5.3 versus 43.0  1.1 min, p <0.001, and 284.5  10.9 versus
185.7  9.8 ml, p <0.001, respectively). At a mean follow-up of 25
months, complete revascularization was associated with a non-sig-
niﬁcant reduction in the risk of all-cause mortality or MI (RR 0.69, 95%
conﬁdence interval (CI) 0.42-1.12, p¼0.14). Complete revasculariza-
tion was associated with a reduced risk of major adverse cardiac
events (MACE) (RR 0.61, 95% CI 0.45-0.81, p<0.001), due to a signif-
icant reduction in urgent revascularization (RR 0.46, 95% CI 0.29-
0.70, p<0.001). The risk of major bleeding and contrast-induced ne-
phropathy was similar with both approaches (RR 0.83, 95% CI 0.41-
1.71, p¼0.62, and RR 0.94, 95% CI 0.42-2.12, p¼0.82).
CONCLUSIONS Complete revascularization of all signiﬁcant coronary
lesions at the time of primary PCI was associated with a reduction inthe risk of MACE due to reduction in the risk of urgent revasculari-
zation. There was a trend towards reduced risk of all-cause mortality
or MI with complete revascularization. This approach appears to be
safe, with no excess major bleeding or contrast-induced nephropathy.
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BACKGROUND Recent randomized trials have failed to demonstrate
clinical beneﬁt from aspiration thrombectomy prior to primary
percutaneous coronary intervention (PCI) in patients with ST-eleva-
tion myocardial infarction (STEMI). However, it is unclear whether
aspects of this procedure (i.e. co-administration of intravenous
glycoprotein IIb/IIIa inhibitors or ischemic time) might modify any
clinical beneﬁts.
METHODS Electronic databases were searched for trials that ran-
domized STEMI patients to aspiration thrombectomy prior to PCI
versus conventional PCI. Summary estimates were constructed using
a DerSimonian-Laird model. Random effects meta-regression for the
logarithm of the relative risk (RR) for various clinical outcomes versus
the average percentage of glycoprotein IIb/IIIa inhibitor usage and
ischemic time were conducted.
RESULTS A total of 17 trials with 20,960 patients were available for
analysis. The weighted mean follow-up duration was 3.7 months.
Aspiration thrombectomy was not associated with a signiﬁcant
reduction in the risk of mortality (relative risk (RR) 0.89, 95% conﬁ-
dence interval (CI) 0.76-1.04, p¼0.13), re-infarction (RR 0.93, 95%
0.73-1.17, p¼0.52), the combined outcome of mortality or re-infarction
(RR 0.90, 0.79-1.02, p¼0.11), major adverse cardiac events (MACE) (RR
0.90, 95% CI 0.81-1.00, p¼0.06), or stent thrombosis (RR 0.82, 95% CI
0.62-1.08, p¼0.15). Aspiration thrombectomy was associated with a
non-signiﬁcant increase in the risk of stroke (RR 1.45, 95% CI 0.96-
2.21, p¼0.08). The ﬁgure summarizes the summary estimates for the
main outcomes assessed. Meta-regression analysis did not identify a
difference for the log RR of mortality, re-infarction, the combined
outcome of mortality or re-infarction, and MACE with intravenous
glycoprotein IIb/IIIa inhibitors (p¼0.17, 0.70, 0.50, and 0.77, respec-
tively) and with ischemic time (p¼0.29, 0.66, 0.58, and 0.16, respec-
tively). Meta-regression for the outcomes of stent thrombosis and
stroke was not possible due to limited studies available for analysis.
CONCLUSIONS Aspiration thrombectomy prior to primary PCI is not
associated with any beneﬁt on clinical endpoints and might increase
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5 B89the risk of stroke. Concomitant administration of intravenous glyco-
protein IIb/IIIa inhibitors and ischemic time did not appear to inﬂu-
ence any potential beneﬁts observed with aspiration thrombectomy.
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BACKGROUND The beneﬁt of transradial primary percutaneous cor-
onary intervention (PPCI) on mortality of patients with ST-segment
elevation myocardial infarction (STEMI) has been shown by several
trials. Previous risk models have not considered access site as a
candidate predictor and most of them were developed using relatively
low risk populations of randomized trials. We conducted a prospec-
tive cohort study to construct and validate a simple admission risk
model for predicting 30-day mortality of STEMI patients undergoing
PPCI. We also aimed to create an internet-based risk calculator.
METHODS The derivation data set consisted of 750 consecutive pa-
tients with a 30-day mortality of 7.6%. We analyzed eight candidate
predictors readily available at or soon after presentation: age, gender,
ECG localization, onset-to-door time, heart rate, systolic blood pressure
(SBP), need for life support on or prior to admission (LS), and access site
(AS). To avoid overﬁtting and determine the best predictors, variable
selection was based on backward stepwise logistic regression using
10,000 bootstrap samples. Restricted cubic splineswere used to explore
presence of non-linear relationships of the continuous predictors to log
odds of 30-day mortality. Besides internal veriﬁcation by boot-
strapping, the model has also been validated externally in an inde-
pendent cohort of 505 patients. Furthermore, we compared the
prognostic capacity of the new score with that of previous risk models.
RESULTS Age (per year, OR: 1.08, p<0.0001, selected in 100.0% of the
bootstrap samples), heart rate (per 1/min., OR: 1.04, p<0.0001, 100.0%), LS
(OR: 6.24, p<0.0001, 98.1%), AS (radial/femoral, OR: 0.48, p¼0.04, 68.0%),
and SBP (selected in 99.7% of the samples) were predictive of 30-day mor-
tality. Since SBP has beenproved to benon-linearly associatedwith the logit
of the outcome, it was represented by two parameters: SBP (permmHg, OR:
0.95, p<0.0001) and SBP’ (permmHg,OR: 1.03, p¼0.03). ROC curve analysis
showed high discriminatory power (apparent c-statistic: 0.88, optimism-
corrected c-statistic: 0.87),whichwas preserved in the validationdata set (c-
statistic: 0.87). Modelﬁt was good in both cohorts (Hosmer-Lemeshow test,
calibration intercept,andslope). For thenewriskmodel theacronymALPHA
(Age, Life support, Pressure, Heart rate, Access site) has been coined.
Compared to previous models, the new model achieved the greatest area
under the ROC curve (0.87) followed by the CADILLAC model (0.85), the
other three risk scoring systems performed somewhat less well (0.82, 0.81,
and 0.78 for the TIMI, Zwolle, and PAMI scores, respectively). Both the
ALPHAandCADILLACmodels predictedbetter than thePAMI score (ALPHA
vs. PAMI: p¼0.005; CADILLAC vs. PAMI: p¼0.02), the remaining pairwise
comparisons revealed no statistically signiﬁcant differences.
CONCLUSIONS Using this simple tool, mortality risk may be precisely
assessed at admission and patients who may beneﬁt most from
transradial PCI may be identiﬁed.
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BACKGROUND ST-segment elevation myocardial infarction (STEMI)
with multivessel (MV) coronary artery disease (CAD) is associated withpoor outcomes. Culprit-lesion only (CLO) vs. MV percutaneous coro-
nary intervention (PCI) revascularization remains uncertain, although
guidelines currently favor CLO.
METHODS To better understand the efﬁcacy and safety of MV vs. CLO
PCI in patients with STEMI we performed a meta-analysis of ran-
domized controlled trials (RCT) that have compared the two revas-
cularization approaches. Electronic databases were searched to
identify RCTs of STEMI patients randomized to either MV PCI or CLO
PCI. The primary efﬁcacy endpoint was major adverse cardiovascular
events (MACE). Secondary endpoints included all-cause mortality,
cardiovascular (CV) mortality, new myocardial infarction (MI), and
repeat revascularization (RRV). Safety endpoints included all-
bleeding, contrast-induced nephropathy (CIN), and stroke.
RESULTS Eight RCTs were included in this meta-analysis enrolling a
total of 2,098 patients. We found that there was a signiﬁcant reduc-
tion in MACE (OR 0.62, 95% CI 0.44-0.88; p¼0.01) CV mortality (OR
0.49, 95% CI 0.28-0.84; p¼0.01) and RRV (OR 0.42, 95% CI 0.33-0.54;
p<0.01) favoring MV PCI. There was a possible reduction in risk of
subsequent MI (OR 0.79, 95% CI 0.55-1.14; p¼0.21) and all-cause
mortality (OR 0.78, 95% CI 0.53-1.14; p¼0.21), with a non-signiﬁcant
trend favoring MV PCI. No differences in safety outcomes were seen
between MV vs. COL PCI; all bleeding events (OR 0.74, 95% CI 0.39-
1.43; p¼0.37), CIN (OR 0.72, 95% CI 0.33-1.54; p¼0.39), and stroke (OR
1.76, 95% CI 0.83-3.74; p¼0.14). The number needed to treat in order
to prevent one CV mortality, RRV or MACE event is 12.5, 50 and 16
patients respectively.
CONCLUSIONS MV PCI signiﬁcantly reduced the rate of MACE, CV
mortality and RRV without signiﬁcant harm as compared to COL PCI.
Although guidelines currently favor CLO over MV PCI revasculariza-
tion, the results of this meta-analysis suggest that clinicians should
consider revascularization of signiﬁcant lesions in non-culprit arteries
in patients with STEMI.
CATEGORIES CORONARY: Acute Myocardial Infarction
KEYWORDS Meta-analysis, Multivessel percutaneous coronary
intervention, ST-segment elevation myocardial infarction
TCT-230
Culprit Lesion Location and Outcome in Patients with Cardiogenic Shock
Complicating Myocardial Infarction: A Substudy of the IABP-SHOCK II-Trial
Georg Fuernau,1 Karl Fengler,2 Steffen Desch,3 Ingo Eitel,4
Franz-Josef Neumann,5 Antoinette de Waha,6 Suzanne de Waha,1
Gert Richardt,7 Klaus Empen,8 Rainer Hambrecht,9 Christian Jung,10
Michael Boehm,11 Janine Pöss,12 Gerhard Schuler,13 Karl Werdan,14
Uwe Zeymer,15 Holger Thiele16
1University of Lübeck Heart Center, Luebeck, Germany; 2University of
Leipzig - Heart Center, Leipzig, Germany; 3University of Schleswig-
Holstein, Campus Lübeck, Lübeck, Germany; 4University of Lübeck,
Lübeck, Germany; 5Universitäts-Herzzentrum Freiburg - Bad
Krozingen, Bad Krozingen, Germany; 6Deútsches Herzzentrum,
Munich, Germany; 7Segeberger Kliniken, Bad Segeberg, Germany;
8University of Greifswald, Greifswald, Germany; 9Klinikum, Bremen,
Bremen, Germany; 10Friedrich-Schiller-University, Jena, Germany;
11Universitaetsklinikum des Saarlandes, Homburg/Saar, Germany;
12University Heart Center Lübeck, Luebeck, Germany; 13University of
Leipzig, Leipzig, Germany; 14Martin Luther University Halle-
Wittenberg, Halle, Germany; 15Klinikum Ludwigshafen, Ludwigshafen,
Germany, Ludwigshafen, Germany; 16University of Schleswig-Holstein,
Campus Lübeck, Lübeck, Germany
BACKGROUND The objective of this study was to determine the
prognostic relevance of the culprit lesion location in patients with
cardiogenic shock (CS) complicating acute myocardial infarction. In
patients without CS the affected coronary vessel with its corre-
sponding area of risk has signiﬁcant inﬂuence on patient prognosis.
For CS data on this relation are scarce.
METHODS In the Intraaortic Balloon Pump in Cardiogenic Shock II
(IABP-SHOCK II) trial patients with CS were randomized to therapy
with intraaortic balloon pump or control. Additional CS patients not
eligible for the randomized trial were included in a registry. We
compared the location of the culprit lesions in these patients with
regard to affected coronary vessel (left main [LM], left anterior
descending [LAD], left circumﬂex [LCX] and right coronary artery
[RCA]) and location within the vessel (proximal or mid/distal)
regarding short- and long-term outcome.
RESULTS Of 758 patients with deﬁned culprit lesions, the majority
had a lesion in the LAD (44%) compared to RCA (27%), LCX (19%) or
LM (10%). Proximal lesions were more frequent than mid/distal
